Транспортные системы — креатин и L-аргинин. Почему не работают?

Единственное из качественных исследований на живых людях. Четыре группы лечения: L-аргинин (9 г. / сут.), креатин (21 г. / сут.), L-аргинин (9 г. / день) плюс креатин (21 г. / день) или плацебо.

Отдельно каждый из препаратов повышал плазменные показатели, но друг на друга влияния не замечено.

Креатин не оказывал существенного влияния на уровни L-аргинина в плазме крови, а L-аргинин не оказывал существенного влияния на уровни креатина.

Автор: Цацулин Борис

Источники:

1. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest. 1997;100:2146–2152. PMC free article PubMed
2. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long- term outcome of coronary heart disease. Circulation. 2000;101:1899–1906. PubMed
3. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948–954. PubMed
4. Gokce N, Keaney JF, Jr, Menzoian JO, Watkins M, Hunter L, Duffy SJ, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function. Circulation. 2002;105:1567–1572. PubMed
5. Girerd XJ, Hirsch AT, Cooke JP, Dzau VJ, Creager MA. L-Arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res. 1990;67:1301–1308. PubMed
6. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248–1253. PMC free article PubMed
7. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol. 1997;80:331–333. PubMed
8. Lerman A, Burnett JCJ, Higano ST, McKinley LJ, Holmes DRJ. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97:2123–2128. PubMed
9. Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanfield JE. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol. 1998;32:110–116. [PubMed]
10. Blum J, Hathaway L, Mincemoyer R, Schenke WH, Kirby M, Csako G, Waclawiw MA, Panza JA, Cannon RO. Oral L-arginine in patients with coronary artery disease on medical management. Circulation. 2000;101:2126–2129. [PubMed]
11. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation. 2007;116:188–195. [PubMed]
12. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang P. Effects of chronic treatment with L-arginine on atherosclerosis in ApoE knockout and ApoE/Inducible NO synthase double-knockout mice. Arterioscler Thromb Vasc Biol. 2003;23:97–103. [PubMed]
13. Schulman S, Becker L, Kass D, Champion H, Terrin M, Forman S, Ernst K, Kelemen M, Townsend S, Capriotti A, Hare J, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: VINTAGE MI (Vascular Interaction With Age in Myocardial Infarction Randomized Clinical) Trial. JAMA. 2006;295:58–64. [PubMed]
14. Castillo L, Beaumier L, Ajami AM, Young VR. Whole body nitric oxide synthesis in healthy men determined from [15N] arginine-to-[15N]citrulline labeling. Proc Natl Acad Sci USA. 1996;93:11460–11465. PMC free article PubMed
15. Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev. 2001;53:161–176. PubMed
16. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80:1107–1213. PubMed
17. Polotskaia A, Wang M, Patschan S, Addabbo F, Chen J, Goligorsky MS. Regulation of arginine methylation in endothelial cells: role in premature senescence and apoptosis. Cell Cycle. 2007;20:2524–2530. PubMed
18. Zhang JG, Liu ZH, Wang LZ, Jiang YD, Wang SR. Dysfunction of endothelial NO system originated from homocysteine-induced aberrant methylation pattern in promoter region of DDAH2 gene. Chin Med J. 2007;23:2132–2137. PubMed
19. Jamaluddin MS, Yang X, Wang H. Hyperhomocysteinemia, DNA methylation and vascular disease. Clin Chem Lab Med. 2007;12:1660–1666. PubMed
20. Loscalzo J. Adverse effects of supplemental L-arginine in atherosclerosis: Consequences of methylation stress in a complex catabolism. Arterioscler Thromb Vasc Biol. 2002;23:3–5. PubMed
21. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna A, Farzati B, Giugliano D. Impairment of endothelial function by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA. 1999;281(22):2113–2118. PubMed
22. Eberhardt RT, Forgione MA, Cap A, Leopold J, Rudd MA, Trolliet M, Heydrick S, Klings E, Moldovan N, Yaghoubi M, Goldschmidt P, Farber HW, Cohen R, Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000;106:383–91. PMC free article PubMed
23. McGuire DM, Gross MD, Van Pilsum JF, Towle HC. Repression of rat kidney L- arginine:glycine amidinotransferase synthesis by creatine at a pretranslational level. J Biol Chem. 1984;259:12034–12038. PubMed
24. Derave W, Marescau B, Eade E, Eijnde B, De Deyn P, Hespel P. Plasma guanidine compounds are altered by oral creatine supplementation in healthy humans. J Appl Physiol. 2004;97:852–857. PubMed
25. Taes Y, Delannghe J, De Vriese A, Rombaut R, Camp J, Lameire N. Creatine supplementation decreases homocysteine in an animal model of uremia. Kidney Int. 2003;64:1331–1337. PubMed
26. Stead LM, Au KP, Jacobs RL, Brosnan ME, Brosnan JT. Methylation demand and homocysteine metabolism: effect of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab. 2001;281:E1095–E1100. PubMed
27. Korzun W. Oral creatine supplementation lowers plasma homocysteine concentrations in humans. Clin Lab Sci. 2004;17:102–106. PubMed
28. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Jr, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996;93:1107–1113. PubMed
29. Vita JA, Frei B, Holbrook M, Gokce N, Leaf C, Keaney JF., Jr L-2-oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J Clin Invest. 1998;101:1408–1414. PMC free article PubMed
30. Bodamer OA, Bloesch SM, Gregg AR, Stockler-Ipsiroglu S, O’Brien WE. Analysis of guanidinoacetate and creatine by isotope dilution electrospray tandem mass spectrometry. Clin Chim Acta. 2001;308:173–178. PubMed
31. Newman DJ, Thakkar H, Edwads RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin c measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:1848–1876. PubMed
32. Larsson A, Malm J, Grubb A, Hansson L-O. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest. 2004;64:25–30. PubMed
33. Widlansky ME, Gokce N, Keaney JF, Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–60. PubMed
34. Clarkson P, Adams M, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clinical Invest. 1996;97:1989–1994. PMC free article PubMed
35. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem. 2000;275:29318–29323. PubMed
36. West SG, Likos-Krick A, Brown P, Mariotti F. Oral L-arginine improves hemodynamic responses to stress and reduces plasma homocysteine in hypercholesterolemic men. J Nutr. 2005;135:212–217. PubMed
37. Joseph J. Hyperhomocysteinemia and cardiovascular disease: new mechanisms beyond atherosclerosis. Metab Syndr Relat Disor. 2003;2:97–104. PubMed
38. Loscalzo J. Homocysteine trials- Clear outcomes for complex reasons. N Engl J Med. 2006;354:1629–1632. PubMed
39. Katusic Z. Mechanisms of endothelial dysfunction induced by aging: Role of arginase I. Circ Res. 2007;101:640–641. PubMed
40. Boger RH. Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Ann Intern Med. 2006;38:126–136. PubMed
41. Kielstein JT, Cooke JP. Should we measure asymmetric dimethylarginine in patients with coronary artery disease? Clin Chem. 2007;53:161–163. PubMed
42. Zoccali CA, Kielstein JT. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease? Current Opinion Nephrol Hypertension. 2006;15:314–320. PubMed
43. Steinberg E, Eknoyan G, Levin N, Eschbach J, Golper T, Owen W, Schwab S. Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: Description, findings, and implications. Am J Kidney Dis. 2000;36:1–11. PubMed
44. Bennett-Richards KJ, Kattenhorn M, Donald AE, Oakley GR, Varghese Z, Bruckdorfer KR, Deanfield JE, Rees L. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int. 2002;62:1372–1378. PubMed
45. Miller HI, Dascalu A, Rassin TA, Wollman Y, Chernichowsky T, Iaina A. Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure. Am J Nephrol. 2003;23:91–95. PubMed
46. Zhang XZ, Ardissino G, Ghio L, Tirelli AS, Dacco V, Colombo D, Pace E, Testa S, Claris-Appiani A. L-arginine supplementation in young renal allograft recipients with chroin renal dysfunction. Clin Nephrol. 2001;55:453–459. PubMed
47. Terjung RL, Clarkson P, Eichner ER, Greenhaff PL, Hespel PJ, Israel RG, Kraemer WJ, Meyer RA, Spriet LL, Tarnopolsky MA, Wagenmakers AJ, Williams MH. American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc. 2000;32:706–717. PubMed
48. Steenge GR, Verhoef P, Greenhaff P. The effect of creatine and resistance training on plasma homocysteine concentration in healthy volunteers. Arch Intern Med. 2001;161:1455–1456. PubMed
49. Taes Y, Delanghe J, DeBacquer D, Langlois M, Stevens L, Geerolf I, Lameire N, DeVriese A. Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients. Kidney Int. 2004;66:2422–2428. PubMed
50. Bostom AG, Bausseman L, Jacques PF, Liaugaudas G, Selhub J, Rosenberg IH. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. Arterioscler Thromb Vasc Biol. 1999;19:2241–2244. PubMed
51. Ferreira LF, Hueber DM, Lutjemeier BJ, Townsend DK, Barstow TJ. Effects of creatine supplementation on body composition and renal function in rats. Med Sci Sports Exerc. 2005;37:1525–1529. PubMed
52. Bostom AG, Gohh RY, Busserman L, Hakas D, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. J Am Soc Nephrol. 1999;10:164–166. PubMed